7 completed, 2 recruiting. 9 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 7, Recruiting 2 |
| Phase 3 | 1 | Completed 1 |
Follow Severe Hypertriglyceridemia: new trials by email Literature Review of Severe Hypertriglyceridemia trials Research Report on Severe Hypertriglyceridemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety, Tolerability and Efficacy of ION775 ION775 - Hypertriglyceridemia, Severe Hypertriglyceridemia | Phase 2 | Recruiting | Ionis Pharmaceuticals, Inc. | 72 | 2026-05-12 | 2026-11-02 |
| A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia Solbinsiran, Placebo - Severe Hypertriglyceridemia | Phase 2 | Recruiting | Eli Lilly and Company | 60 | 2025-12-08 | 2026-11-04 |
| A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia DR10624 Injection, Placebo - Severe Hypertriglyceridemia | Phase 2 | Completed | Zhejiang Doer Biologics Co., Ltd. | 79 | 2024-08-01 | 2026-01-13 |
| A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia Olezarsen, Placebo - Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease | Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 154 | 2022-05-09 | 2026-04-23 |
| Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia ARO-APOC3, Placebo - Severe Hypertriglyceridemia | Phase 2 | Completed | Arrowhead Pharmaceuticals | 229 | 2021-05-31 | 2026-03-24 |
| Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia Pegozafermin, Placebo - Severe Hypertriglyceridemia | Phase 2 | Completed | 89bio, Inc. | 86 | 2020-09-01 | 2024-07-25 |
| A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia Gemcabene, Placebo - Severe Hypertriglyceridemia, Mixed Dyslipidaemia | Phase 2 | Completed | NeuroBo Pharmaceuticals Inc. | 91 | 2016-12-01 | 2020-06-25 |
| Epanova® for Lowering Very High Triglycerides placebo, omefas - Severe Hypertriglyceridemia | Phase 2 / Phase 3 | Completed | AstraZeneca | 399 | 2011-01-01 | 2016-08-04 |
| Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g) - Severe Hypertriglyceridemia | Phase 2 | Completed | AstraZeneca | 54 | 2010-09-01 | 2015-07-15 |
Hypertriglyceridemia (9) · Dyslipidemias (2) · Atherosclerosis (1) · Hyperlipidemias (1) · Lipid Metabolism Disorders (1)
Metabolic Diseases (9) · Nutritional and Metabolic Diseases (9) · Hyperlipidemias (8) · Lipid Metabolism Disorders (8) · Dyslipidemias (7) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Cardiovascular Diseases (1) · Vascular Diseases (1)
Omacor (1) · gemcabene (1) · olezarsen (1)
AstraZeneca (2) · Ionis Pharmaceuticals, Inc. (2) · 89bio, Inc. (1) · Arrowhead Pharmaceuticals (1) · Eli Lilly and Company (1) · NeuroBo Pharmaceuticals Inc. (1) · Zhejiang Doer Biologics Co., Ltd. (1)
United States (8) · Canada (5) · Hungary (3) · China (2) · Netherlands (2) · Poland (2) · Australia (1) · Czechia (1) · Denmark (1) · Germany (1) · India (1) · Japan (1) · New Zealand (1) · Russia (1) · Ukraine (1)
Jianping Li, M.D. (1) · Lee Golden, MD (1) · Michael H Davidson, MD, FACC (1)
PMID 23312053, PMID 24528690, PMID 37355760, PMID 38583092, PMID 38587249